The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children (MobCon)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02854098|
Recruitment Status : Recruiting
First Posted : August 3, 2016
Last Update Posted : March 31, 2017
Benign Hypermobility Joint Syndrome is a group of inherited abnormalities in the structure of connective tissues, manifested by disturbances in the proportion of collagen. The main symptoms of this syndrome include: laxity of joint capsules and ligaments, hypermobility of the joints, as well as numerous disturbances in the functioning of internal organs that contain connective tissue, including the gastrointestinal tract. Hypermobility of joints affects approximately 10% of the population of Western countries, is more common in small children and female. Modified Beighton scale is the basic scale for assessing hypermobility of joints. The scale (as assessed using the goniometer) is a reliable tool for the evaluation of excessive laxity of the connective tissue in children.
Functional constipation is a very common condition, affecting approximately 3-5% of children and adolescents, with peak onset between 2 and 4 years of age. The etiology of this disorder is multifactorial, and till day it is still exactly unknown why some children develop constipation, while in others we can observe the correct scheme of defecation. Suspending stool enhances the retention of fecal masses, which subsequently causes painful defecation. Diagnosis is based on history, clinical symptoms and physical examination. Increased susceptibility of the wall of the distal gastrointestinal tract could explain the predisposition of some children to retain fecal masses and the development of constipation.
Due to the unclear etiology of functional constipation, it seems reasonable to conduct a study assessing whether excessive laxity of connective tissue (assessed on the basis of the hypermobility of the joints) facilitates the accumulation of stool in the large intestine, and so is the one of the reasons leading to development of functional constipation in children.
|Condition or disease|
|Benign Hypermobility Syndrome Functional Constipation|
Clinical question: Is there among patients with functional constipation increased percentage of children with Benign Hypermobility Joint Syndrome, compared with a population of healthy children? In discussion we would like to determine whether the excessive laxity of connective tissue can promote the development of functional constipation in children.
Description of the study:
- Anamnesis and physical examination of the patient
- The consent of the parents and the patient (if > 15 years) to participate in the study
- Determining whether the patient meets the criteria for inclusion in the study
- The exclusion of patients meeting the exclusion criteria for the study - on the basis of anamnesis and physical examination (including neurological) and diagnostic tests (biochemical and electrolyte TSH -, Na, K, Ca, P, Mg), if indicated
- In patients classified to the study, the degree of laxity of the connective tissue will be assessed in the basis of modified Beighton scale
- In the control group - patients without constipation in an interview - the degree of laxity of the connective tissue will be assessed in the basis of modified Beighton scale
- Evaluation of the results.
Rome III Criteria Functional Constipation
Diagnostic criteria must include one month in children up to 4 years of age and two months in older children(with insufficient criteria for diagnosis of IBS) of at least two of the following:
- Two or fewer defecations per week
- At least one episode/week of incontinence after the acquisition of toileting skills
- History of excessive stool retention
- History of painful or hard bowel movements
- Presence of a large fecal mass in the rectum
- History of large diameter stools which may obstruct the toilet Accompanying symptoms may include irritability, decreased appetite, and/or early satiety. The accompanying symptoms disappear immediately following passage of a large stool.
Modified Beighton scale Hypermobility of joints indicates ≥ 4 points out of 9 possible.
The Beighton score is measured by adding 1 point for each of the following:
- Placing flat hands on the floor with straight legs
- Left knee bending backward (>10 °)
- Right knee bending backward (>10 °)
- Left elbow bending backward (>10 °)
- Right elbow bending backward (>10 °)
- Left thumb touching the forearm
- Right thumb touching the forearm
- Left little finger bending backward (>90 °)
- Right little finger bending backward (>90 °)
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||400 participants|
|Target Follow-Up Duration:||1 Day|
|Official Title:||The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||October 2017|
with functional constipation
n = 200 patients with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
without functional constipation
n = 200 patient with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
- The comorbidity of benign hypermobility joint syndrome and functional constipation in children (in %) [ Time Frame: April 2017 ]The Hypermobility of the connective tissue as one of the etiological factors of functional constipation in children
- The comorbidity of BHJS and functional constipation, depending on age (in %) [ Time Frame: April 2017 ]
- The comorbidity of BHJS and functional constipation, depending on gender (in %) [ Time Frame: April 2017 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02854098
|Contact: Andrzej Załęski, MD||+48 600 982 firstname.lastname@example.org|
|Contact: Agnieszka Gawrońska, PhD||+48 22 317 94 email@example.com|
|Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw||Recruiting|
|Warsaw, Mazowieckie, Poland, 02-091|
|Contact: Andrzej Załęski, MD + 48 600982185 firstname.lastname@example.org|
|Study Chair:||Piotr Albrecht, PhD||Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw|